[DOI] [PubMed] [Google Scholar] 89.Jin Y., Duan L., Lee S.H., Kloosterboer H.J., Blair I.A., Penning T.M
For more information on Bio-Techne and its brands, please visit bio-techne.com
Fascia is highly embedded with proprioceptors, making it a major pain generator
Since the data were normally distributed and the variances were homogeneous, parametric tests were utilized
The available evidence consists primarily of animal studies and limited early-phase human trials, with no published phase III clinical trial data demonstrating efficacy in inflammatory bowel disease (IBD).[1][2] The literature describes BPC-157 as a stable gastric pentadecapeptide that was tested in phase II clinical trials for inflammatory bowel disease (referenced as PL 14736), with reports indicating it was "safe" and had "no side effects." However, a 2025 review emphasizes that BPC-157 "has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans."[1][3][2] The preclinical evidence is extensive but limited to animal models
